Pfizer-BioNTech testing booster of their COVID-19 vaccine in new trial




  • In Business
  • 2021-02-25 12:39:03Z
  • By Reuters
 

By Michael Erman

(Reuters) - Pfizer Inc and BioNTech SE said on Thursday they are testing a third dose of their COVID-19 vaccine to better understand the immune response against new variants of the virus.

They are also in talks with regulatory authorities about testing a vaccine modified to protect specifically against the highly transmissible new variant found in South Africa and elsewhere, known as B.1.351, as a second arm of the same study.

The companies believe their current two-dose vaccine will work against the South African variant as well as one found in the United Kingdom and elsewhere. But the studies will allow the vaccine makers to be prepared if and when more protection is necessary, they said.

"The rate of mutations in the current virus is higher than expected," Pfizer Chief Scientific Officer Mikael Dolsten said in an interview.

"It's a reasonable probability that we would end up with regular boosts. And for potent vaccines, it may be that you need to do a strain change every few years, but not necessarily every year."

In the first stage of the first arm of the study, a third 30 microgram dose will be given to as many as 144 people who received the vaccine 6 to 12 months ago in the original Phase I safety trial.

Assuming regulatory approval, a redesigned vaccine would also be tested, both as a booster dose in people who have been vaccinated and in people who had not yet received the vaccine, Dolsten said.

The trial would not seek to measure the efficacy of the vaccine like their large Phase III trial last year. Instead it would measure the antibody response and study whether blood from recipients can neutralize the new coronavirus variants, as well as the safety of a third dose.

The United States discovered its first case of the South African variant in January and it has since turned up in 14 states, according to U.S. government data. Several studies suggest it is more resistant to existing vaccines than other variants of the coronavirus.

Pfizer's Dolsten said that mRNA vaccines like Pfizer and BioNTech's create a potent response. But the immune response may wane over time.

He believes that a third dose of their vaccine will create a similar or better response than the second dose, and could be the logical next step for staying ahead of circulating variants.

"We think our vaccine is robustly active against all strains," Dolsten said, noting that the companies "want to be prepared for all options and be data driven - led by science."

Dolsten said the new trial would likely be predominantly conducted in the United States.

Moderna Inc said on Wednesday it is also working with U.S. government scientists to study an experimental booster shot that targets the variant first found in South Africa.

(Reporting by Michael Erman in Maplewood, N.J.; Editing by Edwina Gibbs)

COMMENTS

More Related News

US recommends
US recommends 'pause' for J&J vaccine over clot reports
  • US
  • 2021-04-13 11:18:53Z

The U.S. is recommending a "pause" in administration of the single-dose Johnson & Johnson COVID-19 vaccine to investigate reports of potentially dangerous...

U.S. calls for pause on Johnson & Johnson
U.S. calls for pause on Johnson & Johnson's COVID-19 vaccine
  • US
  • 2021-04-13 11:10:33Z

The CDC and the U.S. Food and Drug Administration said in a joint statement that the adverse events appear to be extremely rare right now. As of April 12...

Fauci says the US may not even need the AstraZeneca COVID-19 vaccine as it has enough shots for every American
Fauci says the US may not even need the AstraZeneca COVID-19 vaccine as it has enough shots for every American

Dr. Anthony Fauci told BBC radio it "looks like right now" that the US won't need the doses, adding that it's "not a negative indictment" of the shot.

AstraZeneca shot is good if safety issues can be overcome, U.S. official Fauci says
AstraZeneca shot is good if safety issues can be overcome, U.S. official Fauci says
  • US
  • 2021-04-13 06:57:00Z

U.S. infectious disease official Anthony Fauci said AstraZeneca's COVID-19 vaccine had good efficacy, but safety concerns needed to be straightened out and...

Autoimmune-disease drugs may reduce vaccine response; antibody treatments ineffective vs Brazil variant
Autoimmune-disease drugs may reduce vaccine response; antibody treatments ineffective vs Brazil variant
  • US
  • 2021-04-12 19:34:27Z

(Reuters) -The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID...

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

  • Get Athe Assignment Service
    (2021-02-25 19:20:23Z)

    You can Get Athe Assignment Service from professional assignment writers easily. The pricing structure is very reasonable and can be afforded by anyone simply.

    REPLY

Top News: Business